Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$1.61 - $1.96 $53,988 - $65,724
-33,533 Reduced 1.19%
2,790,286 $5.19 Million
Q1 2023

May 15, 2023

BUY
$1.8 - $2.83 $5.08 Million - $7.99 Million
2,823,819 New
2,823,819 $5.48 Million

Others Institutions Holding EQRX

About EQRx, Inc.


  • Ticker EQRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 448,140,992
  • Description
  • EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...
More about EQRX
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.